Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H16F2N4O2S.ClH |
Molecular Weight | 426.868 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12COC[C@@]1(N=C(N)SC2)C3=C(F)C=CC(NC(=O)C4=NC=C(F)C=C4)=C3
InChI
InChIKey=JHHMCINLHBUFHB-GHDSXOKHSA-N
InChI=1S/C18H16F2N4O2S.ClH/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18;/h1-6,10H,7-9H2,(H2,21,24)(H,23,25);1H/t10-,18-;/m0./s1
Molecular Formula | C18H16F2N4O2S |
Molecular Weight | 390.407 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25609634Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24530026
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25609634
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24530026
LY-2886721 is selective and potent BACE1 inhibitor developed by Eli Lilly. It reached phase II of clinical trials against Alzheimer'd disease, but its development was suspended due to possible liver toxicity.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25609634
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25609634 |
20.3 nM [IC50] | ||
Target ID: CHEMBL2525 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25609634 |
10.2 nM [IC50] | ||
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24704031 |
20.3 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
15, 35 or 70 mg capsules orally once daily for 26 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25609634
Human embryonic kidney cell line (HEK293) stably expressing APP751cDNA containing a Swedish mutation (HEK293Swe) was exposed to increasing concentrations of LY2886721(up to 1mkM) and the amount of amyloid_1–40 (A_1–40) and A_1–42 measured in the media as an index of BACE1 inhibition.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:14:34 GMT 2023
by
admin
on
Sat Dec 16 05:14:34 GMT 2023
|
Record UNII |
HW8GJY7V7R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HW8GJY7V7R
Created by
admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
|
PRIMARY | |||
|
100000175602
Created by
admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
|
PRIMARY | |||
|
DTXSID10155116
Created by
admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
|
PRIMARY | |||
|
1262036-49-6
Created by
admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
|
PRIMARY | |||
|
50902942
Created by
admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |